Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUTI: Impact of Corpus Luteum on FET Pregnancies
NCT06896617Phase 4Recruiting
- Sponsor
- Fundació Clínic per a la Recerca Biomèdica
- Start
- Feb 2025
- Primary completion
- Nov 2026
- Modality
- rProtein (Recombinant Protein), Hormone, Biologic
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of recombinant human chorionic gonadotrophin in infertility (3 arms), sponsored by Fundació Clínic per a la Recerca Biomèdica. Primary endpoints: Maternal Relaxin-2 plasma concentrations up to 10 month and Fetal Mitral Annular Plane Systolic Excursion up to 10 month. Started Feb 2025; status: recruiting.
02
Drugs
recombinant human chorionic gonadotrophin
03
Conditions
infertility
Beyond the preview
Go deeper on NCT06896617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06896617.